An experience of treatment of acute bronchitis using thiamphenicol glycinate acetylcisteinate in children

Abstract

The aim of this study was to analyze clinical efficacy and safety of inhaled thiamphenicol glycinate acetylcisteinate (TGA) compared to conventional systemic antibacterial therapy in children with acute bronchitis.

Methods. This was a randomized open postmarketing parallel-group trial which involved 150 children (71 boys) aged 3 to 17 years with acute bronchitis. Children were included to the trial if they did not improve in 5–6 days of a symptomatic treatment or if they had bacterial respiratory infection. The patients were randomly assigned either to nebulized inhalations of TGA or oral macrolides plus oral N-acetylcysteine for 7 days. Efficacy of therapy was assessed by clinical sign scoring and lung function measured by computed bronchophonography.

Results. In 3 days of the treatment, the body temperature decreased to low-grade fever in both the groups. Clinical signs of acute bronchitis improved significantly in 84% of the TGA group patients with statistically significant difference compared to the controls; cough and sputum production were 1.7 ± 0.06 and 2.1 ± 0.02, respectively (р < 0.05); wheezing reduced in 1.5 times in the TGA group to the 3^rd day. To the 7^th day of the treatment, improvement was equal in both the group and clinical efficacy (recovering, improvement, or no change) did not differ between the groups. Systemic antibacterial therapy was not required in the TGA group.

Conclusion. The results have shown the high clinical efficacy of inhaled TGA in children with acute bacterial bronchitis. Systemic macrolides did not improve clinical outcomes and did not shortened the length of the disease, but caused more adverse events compared to the inhaled topic antibacterial therapy.